Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | KAT2B | Q92831 | 5/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26220365 | 0.89 | PDE4D (0.37) | PDE4DPDE4BTNFGAA | |
| SCHEMBL22119157 | 0.88 | PDE4D (0.34) | PDE4DPDE4BTNF | |
| SCHEMBL22118820 | 0.80 | LRRK2 (0.34) | — | |
| SCHEMBL22118863 | 0.80 | TGFBR1 (0.35) | PDE4DTNFMAPT | |
| SCHEMBL22245223 | 0.78 | SCN9A (0.35) | PDE4DPDE4BTNF | |
| SCHEMBL22119117 | 0.78 | MAPT (0.38) | PDE4DMAPT | |
| SCHEMBL22119044 | 0.75 | CCR4 (0.32) | — | |
| SCHEMBL22245124 | 0.75 | CSNK2A1 (0.33) | — | |
| SCHEMBL22118795 | 0.75 | CSNK2A1 (0.33) | — | |
| SCHEMBL22118992 | 0.75 | CYP1A2 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534470-B2 | DNA polymerase IIIC inhibitors and use thereof | Acurx Pharmaceuticals, Inc. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20230250102-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | Acurx Pharmaceuticals, Inc. | 2023-08-10 | — | — | US | disclosed |
| US-20220112195-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | ACURX PHARMACEUTICALS LLC (US) | 2022-04-14 | — | — | US | disclosed |
| US-11001592-B2 | DNA polymerase IIIC inhibitors and use thereof | ACURX PHARMACEUTICALS, LLC (US) | 2021-05-11 | — | — | US | disclosed |
| US-10836772-B2 | DNA polymerase IIIC inhibitors and use thereof | ACURX PHARMACEUTICALS, LLC (US) | 2020-11-17 | — | — | US | disclosed |
| US-20200308180-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | Acurx Pharmaceuticals, Inc. | 2020-10-01 | — | — | US | disclosed |
| US-20200308179-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | Acurx Pharmaceuticals, Inc. | 2020-10-01 | — | — | US | disclosed |
| US-10723741-B1 | DNA polymerase IIIC inhibitors and use thereof | ACURX PHARMACEUTICALS, LLC (US) | 2020-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112195-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | POLI, POLN, POLB | KDM4E 3116/4885PDE4D 1611/4885PDE4B 1290/4885 |
| US-12534470-B2 | DNA polymerase IIIC inhibitors and use thereof | POLR1A, POLR2H, POLN | KDM4E 1267/4885PDE4D 3796/4885PDE4B 2612/4885 |
| US-20200308180-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | POLI, POLN, POLB | KDM4E 3100/4885PDE4D 1545/4885PDE4B 1221/4885 |
| US-20230250102-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | POLI, POLN, POLB | KDM4E 3116/4885PDE4D 1611/4885PDE4B 1290/4885 |
| US-20200308179-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | POLI, POLN, POLB | KDM4E 3100/4885PDE4D 1545/4885PDE4B 1221/4885 |
| US-11001592-B2 | DNA polymerase IIIC inhibitors and use thereof | POLI, POLN, POLB | KDM4E 3100/4885PDE4D 1545/4885PDE4B 1221/4885 |
| US-10723741-B1 | DNA polymerase IIIC inhibitors and use thereof | POLI, POLN, POLB | KDM4E 3116/4885PDE4D 1611/4885PDE4B 1290/4885 |
| US-10836772-B2 | DNA polymerase IIIC inhibitors and use thereof | POLI, POLN, POLB | KDM4E 3100/4885PDE4D 1545/4885PDE4B 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.